This is a prospective, open-label, single center, pharmacokinetic study of anidulafungin in
infants and toddlers less than 24 months of age with suspected serious infection. There will
be up to 24 subjects enrolled; each will receive anidulafungin. Patients will receive
anidulafungin 3 mg/kg loading dose on day 1 of study and will receive 1.5 mg/kg every 24
hours on study days 2-5.Plasma pharmacokinetics will be evaluated using a limited sampling
scheme. We hypothesize that the PK parameters of anidulafungin will not differ from those
observed in older children and adults.